Colorectal Cancer is malignant disease arising in the colon or rectum, the major portions of the large intestine. Most cases are adenocarcinomas arising from glandular epithelial cells, although less common tumour types exist. The disease can occur anywhere along the colon and rectum, and tumour location influences presentation, investigation and sometimes treatment. Colorectal Cancer frequently develops through a multistep process in which normal intestinal epithelial cells accumulate genetic and epigenetic abnormalities. A common pathway involves the development of an adenomatous polyp followed by progressive molecular changes, although alternative pathways also exist. This biological progression creates an opportunity for prevention and early detection because some precursor lesions can be identified and removed before invasive cancer develops.
Risk increases substantially with age, although Colorectal Cancer can occur in younger adults. Important risk factors include a personal or family history of colorectal neoplasia, certain inherited syndromes, inflammatory bowel disease, smoking, alcohol consumption, obesity, physical inactivity and dietary patterns associated with higher consumption of processed or red meat. Lynch syndrome and familial adenomatous polyposis are examples of inherited conditions that can produce substantially increased risk. Risk is not determined by a single factor, and people without obvious risk factors can still develop the disease. Increasing incidence in some younger populations has also made age alone an insufficient explanation for every clinical presentation.
Symptoms depend partly on tumour location and extent. Possible manifestations include rectal bleeding, blood mixed with stool, altered bowel habit, persistent change in stool calibre or frequency, abdominal discomfort, unexplained iron-deficiency anaemia, fatigue and unintended weight loss. Right-sided colon cancers can present with occult blood loss and anaemia, whereas left-sided and rectal tumours may more often produce changes in bowel habit or visible bleeding. These patterns are tendencies rather than diagnostic rules. Benign gastrointestinal conditions can cause similar symptoms, so persistent or unexplained symptoms require appropriate assessment rather than assumptions based solely on symptom appearance.
Screening can detect Colorectal Cancer at an earlier stage and can also identify precursor lesions. Methods include stool-based tests for occult blood, stool DNA-based approaches in some healthcare systems, colonoscopy and other structural examinations. Colonoscopy has the additional advantage of allowing polyps to be removed during the same procedure. Screening programmes differ internationally in age ranges, intervals and preferred tests because recommendations depend on population risk, resources and evidence. A positive stool-based screening result does not itself diagnose cancer; it indicates that further diagnostic investigation is needed. Screening is distinct from investigating symptoms because symptomatic patients require clinical assessment regardless of whether they fall within a routine screening age group.
Diagnosis usually involves colonoscopy with biopsy of suspicious lesions, followed by histopathological examination. Pathology determines tumour type, differentiation and other characteristics, while staging assesses local invasion, regional lymph nodes and distant metastases. CT imaging is commonly used to evaluate the chest, abdomen and pelvis for metastatic disease, while MRI has particular importance in staging rectal cancer. Molecular testing can identify features such as mismatch-repair deficiency or microsatellite instability, which have prognostic and therapeutic implications and can also suggest Lynch syndrome. Molecular classification has therefore become an integral part of modern colorectal oncology rather than an optional research exercise.
Treatment depends on tumour location, stage, molecular characteristics, resectability and overall clinical circumstances. Localised colon cancer is commonly treated surgically, with chemotherapy added for selected stages or risk profiles. Rectal cancer can require combinations of surgery, radiotherapy and systemic therapy, and modern treatment pathways increasingly use neoadjuvant approaches in appropriate patients. Metastatic disease may be treated with combinations of chemotherapy, targeted agents and immunotherapy depending on molecular features. Some patients with limited liver or lung metastases can undergo potentially curative metastasectomy or other local treatments when disease distribution and response make this appropriate.
Colorectal Cancer commonly spreads through lymphatic and blood vessels, with the liver and lungs frequent sites of distant metastasis. The biological pathways involved include chromosomal instability, mismatch-repair deficiency and serrated neoplasia pathways, among others. These pathways help explain why colorectal tumours can differ substantially in mutation profiles and clinical behaviour. Mismatch-repair-deficient or microsatellite-instability-high cancers can be particularly responsive to immune checkpoint inhibition in appropriate settings. Tumour genetics can also have implications for inherited cancer risk, making family history and molecular findings relevant beyond the individual patient.
Colorectal Cancer is significant because prevention, screening and effective treatment can all substantially influence outcomes. Removing precursor polyps can interrupt the progression from premalignant lesion to invasive cancer, while early-stage cancers are generally more amenable to curative treatment than advanced disease. Limitations of screening include false-positive and false-negative results, procedural risks and the possibility of detecting abnormalities whose future significance is uncertain. Prevention involves addressing modifiable risk factors while recognising that inherited susceptibility and unavoidable biological variation remain important. Improvements in molecular classification, systemic therapy, surgical techniques and earlier detection continue to change the management of Colorectal Cancer.
